BackCOSCIENS Biopharma Overview

COSCIENS Biopharma Total Liabilities

Latest total liabilities for AEZS: $24M.

Get informed when a big investor buys or sells

+ Follow
Total Liabilities
$23.82M
36.85% YoYΔ $6.41M vs prior year quarter

Peer trimmed avg / median

Loading

COSCIENS Biopharma Total Liabilities History

Loading

COSCIENS Biopharma vs. peers: Total Liabilities Comparison

Loading

COSCIENS Biopharma Total Liabilities Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

COSCIENS Biopharma (AEZS) FAQ

As of the most recent data (June 2024), AEZS shows a total liabilities of $24M. That compares with $17M in the prior-year period — up 36.9% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, AEZS's total liabilities is now $24M (was $17M) — a 36.9% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether COSCIENS Biopharma is outperforming or lagging.

Tracking AEZS's total liabilities over time shows whether COSCIENS Biopharma is scaling, shrinking, or reshaping that part of the business. The current reading is $24M That compares with $17M in the prior-year period — up 36.9% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this total liabilities page, Stockcircle has COSCIENS Biopharma's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect total liabilities (currently $24M) with ownership activity and broader fundamentals.

COSCIENS Biopharma's total liabilities is $24M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.